芪贞抑瘤方联合生长抑素类似物治疗晚期胰腺神经内分泌肿瘤的回顾性队列研究  

Retrospective cohort study of Qi Zhen Yi Liu Formula and somatostatin analogues in advanced pancreatic neuroendocrine tumors

作　　者：陈儒骜 陈琦双 程梓轩 余芙欢 陈晓莹 谭煌英[2] CHEN Ru-ao;CHEN Qi-shuang;CHENG Zi-xuan(Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]北京中医药大学,北京100029 [2]中日友好医院中西医结合肿瘤内科,北京100029

出　　处：《中日友好医院学报》2024年第3期139-143,共5页Journal of China-Japan Friendship Hospital

基　　金：中日友好医院临床研究与转化跃升项目(2022-NHL-HCRF-LX-02-0110)。

摘　　要：目的:探究芪贞抑瘤方联合生长抑素类似物(SSAs)治疗晚期胰腺神经内分泌肿瘤(PanNETs)的优势。方法:回顾性分析2012年8月—2023年6月就诊于中日友好医院,使用芪贞抑瘤方和/或SSAs治疗的晚期PanNETs患者的病历资料,对临床疗效、安全性和影响无进展生存时间(PFS)的相关因素进行分析。结果:芪贞抑瘤方组(n=5)中位PFS因随访时间较短而未达到,SSAs组(n=7)中位PFS为7.97个月(95%CI:7.63~8.30),芪贞抑瘤方联合SSAs组(n=44)中位PFS为25.00个月(95%CI:22.02~27.99)。中西医联合治疗组显著提高了疾病控制率。肝肿瘤负荷、Ki-67指数和是否切除肿瘤原发灶是PFS的影响因素(P<0.05)。结论:芪贞抑瘤方联合SSAs中西医结合治疗模式,可一定程度地延长晚期PanNETs患者PFS,并明显减少SSAs相关不良反应,改善患者的生活质量。这种联合治疗在肝肿瘤负荷小、低Ki-67指数和原发灶切除的患者中获益更显著。Objective:To explore the advantages of Qi Zhen Yi Liu formula combined with somatostatin analogs(SSAs)in treating advanced pancreatic neuroendocrine tumors(Pan NETs).Methods:A retrospective analysis was conducted on the medical records of patients with advanced Pan NETs treated with Qi Zhen Yi Liu formula and/or SSAs at China-Japan Friendship Hospital from August 2012 to June 2023.The analysis focused on treatment efficacy,safety,and factors influencing progression-free survival(PFS).Results:The median PFS for the Qi Zhen Yi Liu formula group(n=5)was not reached due to insufficient follow-up time,while the SSA group(n=7)had a median PFS of 7.97 months(95%CI:7.63,8.30),and the combined treatment group(n=44)had a median PFS of 25.00 months(95%CI:22.02,27.99).The integrated treatment of traditional Chinese and western medicine significantly improved the disease control rate.Liver tumor burden,Ki-67 index,and whether the primary tumor was surgically removed were independent factors affecting PFS(P<0.05).Conclusion:The combination of Qi Zhen Yi Liu formula and SSAs in treating advanced Pan NETs can prolong PFS,reduce SSA-related adverse reactions and improve quality of life.This combination treatment is particularly effective in patients with a lower liver tumor burden,lower Ki-67 index,and those who have undergone surgical removal of the primary tumors.

关 键 词：胰腺神经内分泌肿瘤 芪贞抑瘤方 生长抑素类似物 无进展生存期 

分 类 号：R735.9[医药卫生—肿瘤]